News stories about Eleven Biotherapeutics (NASDAQ:EBIO) have been trending positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eleven Biotherapeutics earned a coverage optimism score of 0.27 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.6949976532342 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Eleven Biotherapeutics (EBIO) traded up $0.01 on Friday, reaching $0.66. The company’s stock had a trading volume of 516,400 shares, compared to its average volume of 524,443. Eleven Biotherapeutics has a 52-week low of $0.62 and a 52-week high of $2.54.

WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/eleven-biotherapeutics-ebio-given-coverage-optimism-rating-of-0-27/1766374.html.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Insider Buying and Selling by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)

Receive News & Ratings for Eleven Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.